Instent CTO-What Is the Best Treatment Strategy?

Affiliations

¹ Campbell University School of Osteopathic Medicine, Lillington, NC, 27546, USA.
² Division of Cardiology and McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, 27599-7075, USA. rstouff@med.unc.edu.

Editorial

Mark Sahyouni et al. Cardiovasc Drugs Ther. 2024 Jun.

. 2024 Jun;38(3):393-394.

doi: 10.1007/s10557-024-07556-2. Epub 2024 Jan 25.

¹ Campbell University School of Osteopathic Medicine, Lillington, NC, 27546, USA.
² Division of Cardiology and McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, 27599-7075, USA. rstouff@med.unc.edu.

No abstract available

References

1. Giustino G, Colombo A, Camaj A, et al. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(4):348–72. - DOI - PubMed
1. Vemmou E, Quadros AS, Dens JA, et al. In-stent CTO percutaneous coronary intervention: individual patient data pooled analysis of 4 multicenter registries. Cardiovasc Interv. 2021;14(12):1308–19.
1. Azzalini L, Dautov R, Ojeda S, et al. Procedural and long-term outcomes of percutaneous coronary intervention for in-stent chronic total occlusion. Cardiovasc Interv. 2017;10(9):892–902.
1. Lee SH, Cho JY, Kim JS, et al. A comparison of procedural success rate and long-term clinical outcomes between in-stent restenosis chronic total occlusion and de novo chronic total occlusion using multicenter registry data. Clin Res Cardiol. 2020;109:628–37. - DOI - PubMed
1. Alfonso F, Coughlan J, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. Eurointervention J Europcr Collaboration Working Group Interv Cardiol Eur Soc Cardiol. 2022;18(2):e103–23.